Shares of Godavari Biorefineries Ltd. rallied 6.95% to ₹303.90 on Tuesday, June 16, following the company's announcement of a significant patent grant. According to Business Standard, the stock gained momentum after the company disclosed that the Japanese Patent Office had granted a patent for its cancer treatment invention. The positive market response reflects investor confidence in the company's intellectual property portfolio expansion in the healthcare sector.
The company announced that it had been granted a patent by the Japan Patent Office for an invention related to cancer treatment. As reported by Business Standard, the patent has been granted for '5-Hydroxy-1,4-Naphthalenedione for Use in the Treatment of Cancer' and was registered on May 26, 2026, under Patent No. 7869786. The patent application dates back to October 2021 and names Sandeep Gavade, Sangeeta Srivastava, Prashant Karkal and Maithili Athavale among the inventors.
According to Business Standard, the patented invention relates to the use of 5-Hydroxy-1,4-Naphthalenedione in cancer treatment and strengthens its intellectual property portfolio in the healthcare and life sciences space. The patent covers a novel class of compounds that exhibit strong inhibitory effects on cancer cells and cancer stem cells, with demonstrated significant efficacy against multiple cancer types, including breast cancer and prostate cancer. This patent highlights the potential therapeutic applications of these compounds in oncology treatment.
As reported by Business Standard, Godavari Biorefineries is a leading integrated biorefinery focused on the production of bio-based chemicals, ethanol, sugar, and power. The company operates as among the larger ethanol producers in India and is a pioneer in manufacturing ethanol-based chemicals. It operates advanced manufacturing facilities at Sakarwadi in Maharashtra and Sameerwadi in Karnataka, along with three research and development centres located in Mumbai and its plant locations.
On the financial front, Godavari Biorefineries reported mixed results for the quarter ended March 2026. According to Business Standard, the company declined 26.48% in consolidated net profit to ₹52.88 crore compared with ₹71.93 crore in the corresponding quarter of the previous year. Consolidated sales declined 2.66% to ₹564.10 crore during the quarter from ₹579.50 crore recorded in the same period last year. Despite the profit decline, the company continues to focus on expanding its research-driven products and technologies across multiple sectors.
